Commercial Product Sales was Emergent BioSolutions’s largest revenue line in fiscal 2025, bringing in $449.40M of $742.30M (61%).
| Products and Services | FY 2016 | FY 2017 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Product Sales, Net | — | — | — | — | — | |||||
| Product Sales | — | — | — | — | — | |||||
| Commercial Product Sales | $386.60M | $800.00K | — | $797.00M | $449.40M | |||||
| Mcm Product Sales | — | $820.70M | — | — | $156.50M | |||||
| Cost Of Mcm Product Sales | $135.00M | — | — | — | — | |||||
| Services | $105.00M | — | — | — | — | |||||
| All Other Revenues | — | $125.20M | — | $184.90M | $96.80M | |||||
| Contracts & Grants | $41.40M | $26.30M | — | $30.00M | $37.70M | |||||
| Amount Of Revenue Earned From Products Sold Or Services Provided Under The Terms Of A Contract, Including, But Not Limited To, Government Contracts & Grants | — | — | — | — | — | |||||
| Contract Development & Manufacturing Services | — | — | — | — | — | |||||
| Revenue Earned During The Period Arising From Manufacturing Sale Under The Terms Of A Contract | — | — | — | — | — | |||||
| Product & Services Sales, Net | — | — | $50.00M | — | $1.90M | |||||
| Total | $668.00M | $973.00M | $50.00M | $1.01B | $742.30M |
Emergent BioSolutions brought in $742.30M from its five revenue lines in fiscal 2025, the year ended December 31, 2025. Emergent BioSolutions regrouped these revenue lines after fiscal 2024, so the total does not compare directly with that year's $1.01B. Commercial Product Sales was the largest at $449.40M (60.5%), ahead of Mcm Product Sales at $156.50M (21.1%) and All Other Revenues at $96.80M (13.0%). The other two revenue lines brought in $39.60M combined.
Compared with fiscal 2024, Contracts & Grants grew fastest, up 25.7% to $37.70M, while All Other Revenues fell the most, down 47.6% to $96.80M.
Emergent BioSolutions began breaking out Mcm Product Sales in fiscal 2023, All Other Revenues in fiscal 2023 and Product & Services Sales, Net in fiscal 2024. Emergent BioSolutions stopped reporting Cost Of Mcm Product Sales ($135.00M in fiscal 2022) and Services ($105.00M in fiscal 2022) as separate revenue lines.
United States was Emergent BioSolutions’s largest region in fiscal 2025, bringing in $531.10M of $742.90M (71%).
| Geography | FY 2016 | FY 2017 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|
| United States | $886.10M | $607.20M | $822.60M | $531.10M | |||||
| U.S Government | — | — | — | — | |||||
| U.S. Government | — | — | — | — | |||||
| Non-U.S. Government | — | — | — | — | |||||
| Canada | $148.60M | $224.20M | $140.40M | $75.00M | |||||
| Other | $82.80M | $217.90M | $80.60M | $136.80M | |||||
| Total | $1.12B | $1.05B | $1.04B | $742.90M |
Emergent BioSolutions brought in $742.90M from its three regions in fiscal 2025, the year ended December 31, 2025. That was down 28.8% from $1.04B in fiscal 2024. United States was the largest at $531.10M (71.5%), ahead of Other at $136.80M (18.4%) and Canada at $75.00M (10.1%).
Compared with fiscal 2024, Other grew fastest, up 69.7% to $136.80M, while Canada fell the most, down 46.6% to $75.00M. From fiscal 2022 to 2025, combined revenue from these regions fell from $1.12B to $742.90M, a compound annual decline of 12.7%. United States' share of the total fell from 79.3% to 71.5%.
Usg was Emergent BioSolutions’s largest revenue line in fiscal 2025, bringing in $300.20M of $523.50M (57%).
| Customer | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|
| Usg | $444.60M | $373.50M | — | $381.30M | $300.20M | ||
| Non-Usg | $385.80M | $496.50M | — | $398.10M | $223.30M | ||
| Barda | — | — | — | — | — | ||
| Janssen Pharmaceuticals, Inc., | — | — | $50.00M | — | — | ||
| Total | $830.40M | $870.00M | $50.00M | $779.40M | $523.50M |
Emergent BioSolutions brought in $523.50M from its two revenue lines in fiscal 2025, the year ended December 31, 2025. That is less than the $742.90M it reports by geography, so these revenue lines do not cover all of its revenue. Usg was the largest at $300.20M (57.3%), ahead of Non-Usg at $223.30M (42.7%).
Compared with fiscal 2024, Usg fell 21.3% to $300.20M and Non-Usg fell 43.9% to $223.30M.
Emergent BioSolutions stopped reporting Janssen Pharmaceuticals, Inc., as a separate revenue line after fiscal 2024, when it brought in $50.00M.
Emergent BioSolutions (EBS) reports its revenue by products and services, by geography and by customer. In fiscal 2025, Commercial Product Sales was its largest revenue line, bringing in $449.40M (60.5% of the total), followed by Mcm Product Sales at $156.50M (21.1%).
Commercial Product Sales was Emergent BioSolutions' largest revenue line in fiscal 2025, bringing in $449.40M, or 60.5% of the $742.30M total across its five revenue lines.
United States was Emergent BioSolutions' largest region in fiscal 2025, bringing in $531.10M, or 71.5% of the $742.90M total across its three regions.
Among Emergent BioSolutions' regions that make up at least 2% of revenue, Other grew fastest in fiscal 2025, up 69.7% from $80.60M to $136.80M.
Every figure comes from Emergent BioSolutions' annual financial filings, as reported. Each line keeps the name Emergent BioSolutions gives it, and years follow its fiscal calendar.
Emergent BioSolutions' revenue by products and services goes back to fiscal 2016, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.